Drug Profile


Alternative Names: CP-26154; MLR-1023

Latest Information Update: 16 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Bukwang Pharmaceutical; Melior Pharmaceuticals, Inc.
  • Class Antihyperglycaemics; Phenyl ethers; Small molecules
  • Mechanism of Action Lyn protein-tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Sep 2017 Phase-II clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in South Korea (PO)
  • 01 Sep 2017 Phase-II clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in USA (PO) (NCT03279263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top